SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

April 13, 2018: By Jon Swedien

Swiss Advanced Vision (SAV-IOL) is looking to raise $20 million to bring an active intraocular lens with real-time autofocus to market in the next five to 10 years, the company announced April 10.

The Swiss company said it is developing the R-TASC (Real-Time Autofocus Servo Control), an active lens with real-time autofocus and wireless connectivity.

The purpose of R-TASC is to fully restore the accommodative function normally provided by the crystalline lens of the eye, SAV-IOL said.

The R-TASC lens is based on an energy capture system and will focus on any object viewed by the patient in real-time, the company said. SAV-IOL said the platform will also incorporate augmented reality and other interactive or connected features.

The R-TASC will be fitted alongside a monofocal lens (for distance vision) or added on patients who already have a monofocal lens but want to restore their visual accommodation, SAV-IOL said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023